72 research outputs found
PIN22: TELITHROMYCIN (TEL) IS AN EFFECTIVE THERAPY FOR ADULT OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AND IS ASSOCIATED WITH LOWER OVERALL HEALTHCARE COSTS THAN CLARITHROMYCIN (CLA):A POOLED ANALYSIS OF DATA FROM TWO INDEPENDENT, RANDOMIZED, DOUBLEBLIND STUDIES
DB3 THE IMPLICATIONS OF USING A 30-, 60-, OR 90-DAY GAP IN TREATMENT TO SPECIFY LINES OF CARE IN GASTRIC CANCER TREATMENT
Study protocol of cost-effectiveness and cost-utility of a biopsychosocial multidisciplinary intervention in the evolution of non-specific sub-acute low back pain in the working population: cluster randomised trial.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Background: Low back pain (LBP), with high incidence and prevalence rate, is one of the most common reasons to consult the health system and is responsible for a significant amount of sick leave, leading to high health and social costs. The objective of the study is to assess the cost-effectiveness and cost-utility analysis of a multidisciplinary biopsychosocial educational group intervention (MBEGI) of non-specific sub-acute LBP in comparison with the usual care in the working population recruited in primary healthcare centres. Methods/design:
The study design is a cost-effectiveness and cost-utility analysis of a MBEGI in comparison with the usual care of non-specific sub-acute LBP.Measures on effectiveness and costs of both interventions will be obtained from a cluster randomised controlled clinical trial carried out in 38 Catalan primary health care centres, enrolling 932 patients between 18 and 65 years old with a diagnosis of non-specific sub-acute LBP. Effectiveness measures are: pharmaceutical treatments, work sick leave (% and duration in days), Roland Morris disability, McGill pain intensity, Fear Avoidance Beliefs (FAB) and Golberg Questionnaires. Utility measures will be calculated from the SF-12. The analysis will be performed from a social perspective. The temporal horizon is at 3 months (change to chronic LBP) and 12 months (evaluate the outcomes at long term. Assessment of outcomes will be blinded and will follow the intention-to-treat principle. Discussion: We hope to demonstrate the cost-effectiveness and cost-utility of MBEGI, see an improvement in the patients' quality of life, achieve a reduction in the duration of episodes and the chronicity of non-specific low back pain, and be able to report a decrease in the social costs. If the intervention is cost-effectiveness and cost-utility, it could be applied to Primary Health Care Centres. Trial registration:
ISRCTN: ISRCTN5871969
Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence
Yoga vs. physical therapy vs. education for chronic low back pain in predominantly minority populations: study protocol for a randomized controlled trial
A population‐based study comparing multiple sclerosis clinic users and non‐users in British Columbia, Canada
PIN14 OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS: UTILIZATION AND COST
- …